Episode 29: A New Asthma Biologic, Biomarkers for AERD, mHealth for Asthma Nov/Dec 2021 allergytalk

For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
Tezepelumab Reduces Exacerbations – Even at Lower Eosinophil Counts
 
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
 
Predicting Response to Aspirin Therapy in NSAID-ERD
 
Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.
 
Can Technology Aid in Asthma Therapy Adherence?
 
The Impact of Patient Self-Monitoring Via Electronic Medication Monitor and Mobile App Plus Remote Clinician Feedback on Adherence to Inhaled Corticosteroids: A Randomized Controlled Trial.
 
 
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
 
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst